1. Introduction
177Lu is one of the most known and widely used therapeutic radioisotopes in nuclear medicine [
1]. The first clinical application of
177Lu happened in the 1960s; however, the breakthrough in using radiopharmaceuticals based on this radionuclide occurred later with the development of the
177Lu-DOTATATE complex designed to treat neuroendocrine tumors [
2,
3,
4]. Nowadays, the main method of
177Lu production is the irradiation of
176Lu or
176Yb in nuclear reactors, and this production has its disadvantages. Thus, the operation of reactors leads to the accumulation of nuclear waste; irradiation of
176Lu leads to
177Lu with carrier; recovery of
177Lu from neighbor lanthanide Yb is not a simple task [
1]. As a result, other perspective methods of
177Lu production have been investigated recently, the photonuclear one in particular. Today, this method is used for medical isotope production. For instance, light isotopes
11C,
13N,
15O, and
18F as well as radiometals
47Sc,
67Cu, and
99Mo/
99mTc generators are regularly obtained in sufficient quantities using electron accelerators [
5]. Compared to the use of nuclear reactors, the photonuclear method has the following advantages: the compact sizes of electron accelerators that create an opportunity of placing one near the hospital and the relatively cheap cost of accelerators’ functioning. The main disadvantage is cross-sections of photonuclear reactions that are usually lower than ones in reactor production. Data about photonuclear production of
177Lu from hafnium are limited [
6,
7,
8].
One of the issues of
177Lu production is the formation of long-lived isomer
177mLu (T
1/2 = 160.4 d), the content of which should be minimized in
177Lu-based radiopharmaceuticals (the activities ratio of
177mLu and
177Lu should not exceed 0.02 %). The method of
177Lu recovery from irradiated HfO
2 using extraction chromatography was developed by us to determine the amount of formed
177mLu in purified lutetium fractions [
8]; any other techniques of recovery of trace amounts of lutetium from macroquantities of hafnium are absent. However, no gamma-ray peaks of
177mLu were observed during a long registration of the gamma-ray spectrum of purified lutetium solution due to the registration of yttrium isotopes forming from zirconium impurities contained in the initial sample of HfO
2; their Compton plateau in the gamma-ray spectrum overlaps with
177mLu peaks. Consequently, the development of methods of additional purification of recovered
177Lu from forming during irradiation yttrium isotopes is a task of current interest.
The isotope
177Lu can be produced either from hafnium with natural isotopic composition or from enriched
178Hf, which is notably more expensive. It was mentioned that to produce
177Lu with radionuclide purity sufficient for nuclear medicine, it is necessary to irradiate massive (a few grams) targets made of
178Hf [
8] and, as a result, such expensive target material should be reused after the recovery of
177Lu.
The purpose of this work was to develop a promising method of 177Lu production from HfO2 using electron accelerator with subsequent purification from hafnium, zirconium, and especially yttrium, to develop a technique of irradiated HfO2 regeneration, and also to determine the amount of 177mLu produced during this irradiation.
2. Results and Discussion
In our work, a new method of
177Lu production for nuclear medicine was developed: irradiation of HfO
2 with bremsstrahlung photons, its dissolution, and recovery of
177Lu using extraction chromatography; the corresponding scheme is presented in
Figure 1.
2.1. Development of Method of Recovery of 177Lu from Macroquantities of Hafnium and Zirconium, Trace Amounts of Yttrium Isotopes
Method of
177Lu recovery from irradiated HfO
2, developed previously by us, included the following steps: target material dissolution in HF
conc and dilution of the obtained solution fifteen times with 1 M HNO
3; sorption of lutetium on the column filled with LN resin (based on di(2-ethylhexyl)orthophosporic acid); rinsing the column with 1 M HNO
3 and 0.1 M HF mixture and then with 1 M HNO
3 for the remaining hafnium and for fluoride ion removals, accordingly; and, finally, rinsing with 6 M HNO
3 to desorb
177Lu [
8]. To further purify
177Lu from yttrium, the step of column rinsing with 2.5 M HNO
3 was introduced before the desorption of
177Lu; this solution was proved to be the optimal media for quantitative desorption of yttrium according to the conducted experiments (see
Supplementary Section).
Table 1 contains data on the content of hafnium, zirconium, yttrium, and lutetium in eluates obtained during different stages of the developing technique; a chromatogram is presented in
Figure 2.
It was established that hafnium and zirconium did not sorb onto the column during the sorption of lutetium; however, approximately 60% of yttrium was sorbed. Yttrium quantitatively desorbed during the column rinsing with 2.5 M HNO3, while lutetium remained on the column. During the subsequent rinsing with 6 M HNO3, 177Lu quantitatively (no less than 98%) desorbed from the column.
Hafnium content in the obtained solution of lutetium was lower than the detection limit of ICP-MS. This led to the conclusion that the real content of hafnium in the
177Lu solution during the recovery following this method is 1.2 × 10
10 times lower compared to the content in the initial solution, which is five orders of magnitude higher than the result obtained by us earlier [
8]. Zirconium content in the final product, according to ICP-MS, is 1.7 × 10
6 times lower than in the initial solution. As for the purification of lutetium from yttrium, no peaks of yttrium isotopes were detected in a gamma-ray spectrum of lutetium solution aliquot during prolonged registration. Thus, according to the detection limit of
88Y, yttrium content in the final solution was 10
4 times lower than in the initial one.
2.2. Recovery of 177Lu from Irradiated HfO2, Determination of 177mLu Content, and Regeneration of HfO2
A target with a mass of 16 g was irradiated with bremsstrahlung photons with energy up to 55 MeV for 8 h; then, it was dissolved in HF, and the recovery was conducted according to the technique described above. It was established that the purification degree was achieved as outlined above, and the lutetium yield was 98.5 ± 0.5%.
The high purification level of lutetium from macroquantities of hafnium, zirconium, and trace amounts of yttrium, formed during the irradiation of zirconium achieved in our work, allowed us to detect
177mLu peaks during prolonged registration of the gamma-ray spectrum of the obtained lutetium.
Figure 3 presents the dependency of count rate of the 208 keV line, which is the most intense for both
177Lu and
177mLu, on time after the lutetium isotope’s recovery. It can be seen in
Figure 1 that it is possible to determine the contribution of
177mLu in the count rate of this line after
177Lu decay, which allows us to precisely determine the radioactivity of
177mLu after the irradiation. Thus, the ratio of the activity of
177mLu to the activity of
177Lu in the photonuclear production of
177Lu was established to be (2.87 ± 0.07) × 10
−5 (or 0.00287%).
Table 2 allows us to compare the activity ratios
177mLu/
177Lu in production by different methods, and it is clear that the ratio in case of the photonuclear method is minimal among direct production routes, and
177Lu obtained by this method can be used in nuclear medicine.
According to X-ray diffraction (XRD), the spectra of commercial HfO2 and the product of calcination of hafnium hydroxide obtained during the recovery of 177Lu are identical, and values of interplanar distances coincide with the values for HfO2 from the database. Thus, after heating, HfO2 can be stored to decrease activity of hafnium isotopes if necessary, and can be reused for irradiation for 177Lu production.
2.3. Comparison of Methods of Obtaining Carrier-Free 177Lu
We demonstrated the possibility of producing and separating 177Lu for nuclear medicine using electron accelerators. In conclusion, we present a comparison of this method and the production of 177Lu without a carrier in a reactor and a cyclotron.
In the case of
176Yb irradiation in the reactor, it is possible to produce 1.8 GBq of
177Lu (therapeutic activity) by irradiating 5 mg of 97.6%
176Yb
2O
3 for 10 days using flux of 1 × 10
14 n∙cm
−2∙s
−1 [
12]. According to calculations based on experimental data, the same activity of
177Lu can be obtained by irradiating a 100 µm plate of 100%
176Yb with deuterons for about 2 h at a current of 0.1 mA [
13]. According to our earlier theoretical calculations, 1.8 GBq of carrier-free
177Lu can be produced in an electron accelerator by irradiating an enriched
179HfO
2 target at a current of 0.1 mA [
8]. However, it is important to note that the results of calculating the yields of photoproton reactions are usually underestimated from several times to several orders of magnitude. Thus, the determination of the experimental values of
177Lu yields upon irradiation of enriched targets made of
178Hf or
179Hf is an urgent problem.
As for the separation of
177Lu from irradiated Yb targets, the process takes a long time, and the loss of
177Lu can reach 15% [
12]. At the same time, in the present work, we demonstrated the possibility of rapid and quantitative recovery of
177Lu from irradiated HfO
2. When
177Lu is produced in a reactor, the long-lived
177mLu isomer is completely absent [
10]; when produced in an electron accelerator, isomer activity is 0.00287% of the activity of
177Lu; and during cyclotron production, isomer activity does not exceed 0.0045% of
177Lu one [
11].
It is difficult to compare the cost of 177Lu obtained by different methods for a number of reasons. The cost of production in the reactor is the lowest, but this method has disadvantages mentioned in the Introduction, including radioactive waste generation. Per unit of time, a higher 177Lu activity is generated in the cyclotron than in an electron accelerator; however, the cost of the operation of the latter is lower. Finally, it is worth considering that the regeneration of HfO2 targets is easy, as we demonstrated, while 176Yb is usually not regenerated.
As a result, each of the described methods has its advantages and disadvantages, and each can be used to obtain 177Lu for nuclear medicine purposes. In any case, it is currently possible to produce 177Lu for preclinical studies in electron accelerators. Further development of the photonuclear method for obtaining 177Lu consists of establishing the exact values of the yields of the desirable isotope after irradiation of different enriched hafnium targets.
3. Materials and Methods
3.1. Irradiation of HfO2
natHfO
2 with a weight of 16 g was placed in cylindrical polypropylene container with a volume of 5 mL; the remaining space in container was filled with cotton wool. The container was then irradiated for 8 h in RTM-55 microtron with maximum energy of electron beam being 55 MeV [
14]. Tungsten plate of 2 mm thickness was used as an electron convertor; the usual value of average current was 100–200 nA for used accelerator. During radiochemical analysis of irradiated target isotopes
177,178,179Lu,
173,175Hf,
89Zr, and
88Y were found; the same isotopes were also observed in our work [
8].
3.2. Target Dissolution, Recovery of 177Lu, and Regeneration of HfO2
Irradiated HfO2 was dissolved in HFconc by boiling for 1.5 h. Obtained solution was diluted 15 times with 1 M HNO3, resulting in approximately 260 mL.
Four identical columns with volume of 3 mL and diameter of 0.6 cm each, filled with LN resin (100–150 mesh, Triskem Int, Bruz, France), were used in following recovery by extraction chromatography. The solution was divided into 4 equal portions; each was eluted through its own column. Fractions of 5 mL each were gathered during the elution; their gamma-ray spectra were registered using spectrometer with high-purity germanium detector Canberra GC1020 (Canberra Ind, Meridan, CT, USA). Content of hafnium, zirconium, and lutetium in fractions during recovery process was determined using gamma-peaks of the following isotopes: 177Lu (208.4 keV), 175Hf (343.4 keV), 89Zr (909 keV). Content of yttrium was determined during prolonged registration of spectra using 88Y peak (898 keV).
Regeneration of hafnium from the initial solution eluted through the column was conducted by adding ammonia to form precipitate of hafnium hydroxide. This precipitate was separated from the solution by filtration and then was heated for 4 h at 850 °C until the formation of HfO2. XRD spectra (Miniflex 600, Rigaku Corporation, Tokyo, Japan) of obtained product were compared to the spectra of initial HfO2 using database PDF-2.
Study of yttrium behavior on LN resin was carried out by determination of distribution coefficients using 90Y tracer. Content of 90Y in solutions was determined by liquid scintillation spectrometry (LS-spectrometer GreenStar, Moscow, Russia) using liquid scintillation cocktail UltimaGold (PerkinElmer Inc., Shelton, CT, USA), taking into account efficiency calibration for acid concentration.
3.3. Determination of Purification Degree of 177Lu and 177mLu Content
1 mL was taken from fractions containing purified lutetium (80 mL) to determine its hafnium and zirconium content using quadrupole mass-spectrometer with inductively coupled plasma X-series II (Thermo Fisher Scientific, Dreieich, Hessen, Germany). Remaining lutetium solution was evaporated to dryness on a round steel plate with a diameter of 2 cm to determine content of
177mLu and purification degree of
177Lu by radiometry. Activity of plate then was measured several times for the following 270 days using gamma-ray spectrometer with high-purity germanium detector GC3019 (Canberra Ind). Calibration of count efficiency depending on the energy of registered isotope was conducted using measurements of activity of certified point sources (
152Eu,
137Cs,
60Co,
241Am) in different location geometries of source and detector and was also modeled in GEANT4. Identification of peak maximum in spectra was carried out using automatic system of spectrum record and analysis, specially created for this purpose. Thus, spectra with duration of 3.5 s each were saved into the database, and analysis system allowed us to summarize them and display total spectrum with assigned duration [
15].
Purification degree of 177Lu from macroquantities of Hf and Zr was calculated by dividing the mass of Hf or Zr in the initial solution by the mass of ones in purified lutetium solution using ICP-MS data. Purification degree of 177Lu from microquantities of 88Y was determined by gamma-ray spectrometry.
4. Conclusions
A method of recovery of carrier-free 177Lu from macroquantities of hafnium and zirconium and trace amounts of yttrium was developed; the yield of lutetium was not less than 98%. Contents of hafnium, zirconium, and yttrium in the obtained solution of 177Lu were at least 1.19 × 1010, 1.7 × 106, and 104 times lower compared to the initial solution. The achieved level of 177Lu purification allowed us to determine the activity of 177mLu during the prolonged registration of the gamma-ray spectrum, resulting in determination of the 177mLu/177Lu activities ratio that reached a value of (2.87 ± 0.07) × 10−5 for the photonuclear method at the studied energy; this ratio indicates a high purity of the obtained 177Lu and the possibility of its use in nuclear medicine. The developed method was successfully applied to obtain 177Lu after the irradiation of 16 g of HfO2 in an electron accelerator. It was demonstrated that irradiated HfO2 could be quantitatively regenerated and later be reused for the production of the medical isotope 177Lu.
Thus, we demonstrate that it is possible to produce and quantitatively recover 177Lu for preclinical studies using an electron accelerator. Moreover, the photonuclear production of 177Lu can also become an alternative method for its obtaining, but to date, an experimental study of the yields of photoproton reactions on enriched targets made of 178Hf and 179Hf is required.